ABS AUCKLAND BIOSCIENCES EXCELLENCE
LIVE

Serial Number

79229849

Owner

AUCKLAND BIOSCIENCES LIMITED

Attorney

Theodore R. Remaklus

Filing Date

Nov 20, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ABS AUCKLAND BIOSCIENCES EXCELLENCE Trademark

Serial Number: 79229849 • Registration: 5742096

ABS AUCKLAND BIOSCIENCES EXCELLENCE is a trademark filed by AUCKLAND BIOSCIENCES LIMITED on November 20, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

AUCKLAND BIOSCIENCES LIMITED

22A William Pickering Drive,

Entity Type: 16

Trademark Details

Filing Date

November 20, 2017

Registration Date

May 7, 2019

Published for Opposition

February 19, 2019

Goods & Services

[ Pharmaceuticals, medical and veterinary preparations, namely, vaccines for medical or veterinary use; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; material for stopping teeth, dental waxes; all purpose disinfectants; disinfectants for sanitary purposes; disinfectants for hygiene purposes; preparations for destroying vermin; fungicides, herbicides; surgical implants comprised of living tissues; placenta and placenta extracts for medical, medicinal, or veterinary purposes, namely biological tissue cultures; human and animal organs and organ extracts for medical, medicinal, or veterinary purposes, namely biological tissue cultures and implants compromising living tissue; biological implants, namely, living organs for use as surgical implants or transplants; biological tissue, namely, blood, stem cells, umbilical cords and placentas for medical use, in the nature of biological tissue intended for subsequent implantation or for use in developing, producing, and manufacturing vaccines; vaccines; hemoglobin; media for bacteriological cultures; bacteriological culture mediums; cultures of microorganisms for medical and veterinary use; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes, namely, vaccines for medical or veterinary use; chemical preparations for medical purposes, namely, vaccines for medical or veterinary use; blood for medical purposes; blood plasma; [ blood components, namely serums for medical and veterinary use, in the nature of animal or human serum intended for subsequent implantation or for use in developing, producing, and manufacturing vaccines ] [ ; stem cells for medical purposes; stem cells for veterinary purposes; nutritional supplements ]

[ Scientific and technological services and research and design relating thereto, namely research, testing, design, and development, in the field of developing, producing, and manufacturing pharmaceutical products, veterinary products, and vaccines; industrial analysis and research services, namely, industrial research in the field of developing, producing, and manufacturing pharmaceutical products, veterinary products, and vaccines; design and development of computer hardware and software; scientific laboratory services; scientific and industrial research, namely, scientific research in the field of developing, producing, and manufacturing pharmaceutical products, veterinary products, and vaccines; research and development of new products for others; scientific research; technical research in the field of developing, producing, and manufacturing pharmaceutical products, veterinary products, and vaccines; chemical analysis; chemical research; chemistry services in the nature of chemistry consultation in the field of developing, producing, and manufacturing pharmaceutical products, veterinary products, and vaccines; cosmetic research; bacteriological research; biological research; scientific and industrial testing services, namely design and testing for new product development in the field of developing, producing, and manufacturing pharmaceutical products, veterinary products, and vaccines; clinical trials for others in the field of developing, producing, and manufacturing pharmaceutical products, veterinary products, and vaccines ]

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 27, 2026 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Aug 27, 2025 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Aug 27, 2025 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 25, 2025 APRE
TEAS SECTION 71 RECEIVED
May 27, 2025 ES71
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 2, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 2, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 2, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 2, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 2, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 2, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 2, 2024 COAR
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 7, 2024 REM3
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 12, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 12, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 12, 2022 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 20, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 30, 2019 FICS
FINAL DISPOSITION PROCESSED
Aug 30, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 7, 2019 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 20, 2019 ADCH
REGISTERED-PRINCIPAL REGISTER
May 7, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 19, 2019 NPUB
PUBLISHED FOR OPPOSITION
Feb 19, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Feb 15, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 30, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 30, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 30, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 8, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 19, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 19, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 19, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 19, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 13, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 13, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 13, 2018 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 17, 2018 GNFN
FINAL REFUSAL E-MAILED
Oct 17, 2018 GNFR
FINAL REFUSAL WRITTEN
Oct 17, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 19, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 19, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 19, 2018 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Jun 22, 2018 NREP
REFUSAL PROCESSED BY IB
May 4, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 17, 2018 RFCS
REFUSAL PROCESSED BY MPU
Apr 17, 2018 RFRR
APPLICATION FILING RECEIPT MAILED
Apr 14, 2018 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 12, 2018 RFCR
NON-FINAL ACTION WRITTEN
Apr 11, 2018 CNRT
ASSIGNED TO EXAMINER
Apr 10, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 10, 2018 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 9, 2018 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 5, 2018 REPR